WRONG MARKET
US-first by default
Pursuing the largest market first when reimbursement timelines, comparator data, or COGS would have made a smaller geography the better proving ground.
Market Sequencing & Execution
Sequence fırst. Then execute.
Your market sequencing & execution partner for complex biotech & medtech launches.
Decide which markets to enter, in which order — then lead the work to get there.
Why launches stall
The market you launch in first decides what every other market is willing to pay.
NO FOCUS
All markets, in parallel
Spreading consultants and capital across six geographies because no one made the call — losing focus, exceeding burn, and missing every milestone.
NO STRATEGY
Reactive, not sequenced
Following inbound interest from local partners or KOLs instead of a strategy. Each market looks rational in isolation; the portfolio is incoherent.
The fix isn't more activity. It's a defensible order — chosen for spillover effects, evidence quality, and what the access infrastructure can actually deliver.
Who we are
A central path through complex markets.
CEN — central
Anchored strategy, principal-led, accountable.
VIA — path
A sequenced route, not a single bet.
We help biotech and medtech innovators decide which markets to enter, in which order — then lead the regulatory, access, and evidence work to get there. With principals on the call, and modality consultants on the bench.
Our point of view
Sequence ıs strategy. The order of markets compounds value.
01
First market sets the comparator.
The price and access terms in market one become the reference for markets three through eight. Choose for evidence quality, not just size.
02
Sequencing is a portfolio decision.
Markets are correlated. Pricing in Germany affects Japan. UK NICE outcomes echo into the Gulf. Order matters because spillover is real.
03
The fastest path is rarely the largest.
Smaller, earlier markets can deliver real-world data, ex-US revenue, and credibility on a timeline the US cannot match.
04
Execution and sequencing are one decision.
A sequence is only as good as the team that can run it. We design the order around what your launch infrastructure can actually deliver.
Phase 1 · Where to start
Start with a Sequencing Assessment.
A fixed-fee engagement that gives your board a defensible answer to a single question — where do we go first, and why? Delivered in weeks. No hourly meter. No scope creep.
Ranked market sequence
Top markets ordered, with second-tier alternatives flagged.
Rationale by market
Regulatory pathway, reimbursement view, competitive density, evidence fit.
Investment & timeline view
What each of the first three markets costs to launch, and over what horizon.
Execution roadmap
Which Cenvia pillars activate where, and in what order, to run the sequence.
Phase 2 · Execution
Once the order is locked, three delivery modes carry the work.
Launch Studio, Market Accelerator, and Adoption Strategy are how Cenvia delivers — not three separate offerings to choose between. Each market on your sequence activates the right combination, in the right order.
01
Launch Studio
Set up the launch. Regulatory strategy, HTA and reimbursement submissions, pricing frameworks, and evidence planning in the first markets on your sequence.
02
Market Accelerator
Open subsequent markets faster by reusing dossiers, evidence, and stakeholder relationships built upstream.
03
Adoption Strategy
Design the post-launch strategy — KOL engagement, real-world evidence, and patient pathway work that sets your commercial team up to drive uptake.
How we staff
Principals own outcomes. Modality consultants supply depth.
Principals
Senior operators who have run launches end-to-end. They sit in the room with your CEO and board, own the sequencing call, and stay accountable from kick-off through adoption.
- — Continuous across the engagement
- — Direct line to your executive team
- — Accountable for outcomes, not deliverables
Modality consultants
A vetted bench of specialists matched to the asset and market — cell & gene therapy, rare disease, oncology, AI/SaMD, surgical robotics, diagnostics. Activated when the work demands their depth, retired when it does not.
- — Modular: staffed only when needed
- — Vetted by principals before activation
- — Embedded under principal oversight
Geographic reach
We sequence across regions most firms treat as edge cases.
United States
FDA strategy, payer landscape, IDN access — without making the US the default first market.
Europe
EMA, NICE, G-BA, HAS. Reference pricing chains modeled, not assumed.
MENA & GCC
Saudi FDA, UAE MOH, Egypt, Israel. White-space markets where evidence and timing matter.
Asia-Pacific
Japan PMDA, China NMPA, Korea, Australia. Sequenced for HTA spillover and partner economics.
Who we're built for
Biotech and medtech innovators with global ambition.
We work best with
- →
Biotechs
Pivotal data on the horizon, capital deployed, board pre-IPO.
- →
Medtechs
With regulatory, reimbursement, or evidence complexity.
- →
Innovative assets
Novel mechanisms where the comparator and HTA strategy are unsettled.
- →
Multi-region ambition
Plans that already extend beyond a single home market.
Sequence fırst.
Then execute.
If a launch is on your eighteen-month horizon, a Sequencing Assessment is the cheapest decision you'll make.